RxDoctor Payments DataLook up a doctor →

Gary Kao, MD

Interventional Pain Medicine · Middleburg, FLNPI 1346582095

Payments from drug & device makers

$1,128,318in general payments, 2019–2025

Across 436 payments — averaging $2587.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$1.1M
  • Boston Scientific$5K
  • Medtronic$3K
  • Spinal Simplicity, LLC$2K
  • Vertos Medical, Inc.$2K
  • Painteq LLC$1K
  • plus $8K from 37 others

What the payments were for

  • Travel & lodging$7,49130%
  • Food & beverage$17,59570%
  • Gifts$500%
  • Entertainment$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,128,318 in reported general payments places this provider in the 95th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$457,322
Medicare patients
554
Services billed
7,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl123$113,540
Xtampza ErOxycodone Myristate63$31,047
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,137$29,317
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen793$26,067
UbrelvyUbrogepant12$18,956
Buprenorphine82$16,865
OxycontinOxycodone Hcl25$12,417
Hysingla ErHydrocodone Bitartrate29$11,118
Pregabalin316$6,220
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl50$5,768
Gabapentin388$4,352
Oxycodone Hcl273$3,682
Tramadol Hcl ErTramadol Hcl55$3,590
Fentanyl31$2,879
Tizanidine Hcl150$1,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$642$144,587186 claims
AbbVieUbrelvy$239$18,95612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Middleburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →